Key Highlights
- Senti Biosciences (NASDAQ:SNTI) stockholders approved a Merger on October 15, 2026 under which no cash is paid at closing, according to the company filing, and holders receive contingent value rights of up to USD 60.0 million in total.
- The rights pay USD 10.0 million on a regulatory filing acceptance for SENTI-202, USD 20.0 million on FDA approval and USD 30.0 million if cumulative net sales exceed USD 200.0 million, all within seven years.
- Stockholders also approved a reverse split between 1-for-20 and 1-for-50. Convertible notes mature November 23, 2026 at 200% of principal and are expected to convert into about 46.8 million shares at USD 0.342.
- Published market data show SNTI at USD 0.19, up 13.87% in the latest session on 896.82 thousand shares, with a Market Value of USD 5.86 million. These screener figures are unverified.
What the Merger Delivers
Senti Biosciences held its reconvened annual meeting on October 15, 2026 and approved a merger agreement dated July 14, 2026 with ST NewCo Limited. Under the filed terms, no cash was paid at closing. Each common share instead carries one contingent value right, a security that pays only if defined milestones are met. The milestones depend on SENTI-202, a cell therapy candidate, reaching a regulatory filing acceptance, FDA approval and cumulative net sales above USD 200.0 million, all within seven years. Senti Biosciences (NASDAQ:SNTI) shares therefore trade on the value of a right whose payout is uncertain and distant.
Notes, Dilution and the Reverse Split
Penny stock screens list low priced shares, and Senti sits well below USD 1. The filing says convertible notes of USD 10.0 million issued in May 2026, plus USD 4.0 million and USD 2.0 million of additional notes, mature November 23, 2026 at 200% of principal. They are expected to be exchanged for about 46.8 million shares at USD 0.342, and the parent will buy USD 2.5 million of stock at the same price. Existing shares outstanding were about 31.1 million, so the new issuance is large relative to the base, our own arithmetic on the published numbers. Holders approved a reverse split of 1-for-20 to 1-for-50, which raises the price per share without changing the value of a holding.
Risks and What to Watch
A small number of trades can move a stock this size, spreads can be wide and a quoted gain such as 13.87% can reverse quickly, so it should not be read as a trend. The company said it may be unable to maintain operations as early as the fourth quarter of 2026 without additional capital. The USD 60.0 million is a maximum, depends on regulatory and commercial milestones years away, and is divided among all holders. The filing cited a share price of USD 0.23 on October 20, 2026. Investors should watch the closing date, the reverse split ratio and any Nasdaq notice. The filing also shows a loss on disposal of about USD 6.7 million, a preliminary estimate that depends on the closing date and the share price, and a consulting arrangement with the divested Business for an initial 12 months.
Where Things Stand
Holders can count on very little of the USD 60.0 million. It is a ceiling that depends on SENTI-202 gaining regulatory approval and then reaching more than USD 200.0 million of cumulative sales, and no cash was paid at closing. Senti Biosciences (NASDAQ:SNTI) shares now reflect a contingent right, large note conversions at USD 0.342 and a Going Concern warning, which makes this a high risk name where the latest 13.87% rise carries little information.






Please wait processing your request...